EGFR and non-small cell lung carcinoma: Recently conducted clinical trials on osimertinib and bevacizumab have failed to demonstrate any improvement in either PFS or OS as compared to osimertinib alone among patients suffering from NSCLC with an EGFR mutation, regardless of whether they are undergoing first-line (24) or second-line treatment (50).